Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 240

Similar articles for PubMed (Select 10463165)

1.
2.

Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans.

Cruz MC, Cavallo LM, Görlach JM, Cox G, Perfect JR, Cardenas ME, Heitman J.

Mol Cell Biol. 1999 Jun;19(6):4101-12.

3.

Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.

Cruz MC, Goldstein AL, Blankenship J, Del Poeta M, Perfect JR, McCusker JH, Bennani YL, Cardenas ME, Heitman J.

Antimicrob Agents Chemother. 2001 Nov;45(11):3162-70.

4.

Molecular characterization of a plant FKBP12 that does not mediate action of FK506 and rapamycin.

Xu Q, Liang S, Kudla J, Luan S.

Plant J. 1998 Aug;15(4):511-9.

PMID:
9753776
5.

Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast.

Hemenway CS, Heitman J.

J Biol Chem. 1996 Aug 2;271(31):18527-34.

6.
7.

FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.

Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE.

Eur J Immunol. 1995 Feb;25(2):563-71.

PMID:
7533090
8.

Calcineurin is required for virulence of Cryptococcus neoformans.

Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J.

EMBO J. 1997 May 15;16(10):2576-89.

9.

Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue.

Stan R, McLaughlin MM, Cafferkey R, Johnson RK, Rosenberg M, Livi GP.

J Biol Chem. 1994 Dec 23;269(51):32027-30.

10.

Design and synthesis of a rapamycin-based high affinity binding FKBP12 ligand.

Chakraborty TK, Weber HP, Nicolaou KC.

Chem Biol. 1995 Mar;2(3):157-61.

PMID:
9383417
11.

Genetically engineered analogs of ascomycin for nerve regeneration.

Revill WP, Voda J, Reeves CR, Chung L, Schirmer A, Ashley G, Carney JR, Fardis M, Carreras CW, Zhou Y, Feng L, Tucker E, Robinson D, Gold BG.

J Pharmacol Exp Ther. 2002 Sep;302(3):1278-85.

12.

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin.

Cardenas ME, Zhu D, Heitman J.

Curr Opin Nephrol Hypertens. 1995 Nov;4(6):472-7. Review.

PMID:
8591053
13.
14.

Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species.

Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS.

J Antimicrob Chemother. 2003 Feb;51(2):313-6.

15.
16.

Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins.

Weiwad M, Edlich F, Kilka S, Erdmann F, Jarczowski F, Dorn M, Moutty MC, Fischer G.

Biochemistry. 2006 Dec 26;45(51):15776-84. Epub 2006 Dec 19.

PMID:
17176100
17.

Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate.

Andexer JN, Kendrew SG, Nur-e-Alam M, Lazos O, Foster TA, Zimmermann AS, Warneck TD, Suthar D, Coates NJ, Koehn FE, Skotnicki JS, Carter GT, Gregory MA, Martin CJ, Moss SJ, Leadlay PF, Wilkinson B.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4776-81. doi: 10.1073/pnas.1015773108. Epub 2011 Mar 7.

19.

Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans.

Fox DS, Cruz MC, Sia RA, Ke H, Cox GM, Cardenas ME, Heitman J.

Mol Microbiol. 2001 Feb;39(4):835-49.

PMID:
11251806
20.

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.

Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH.

Cell. 1994 Jul 15;78(1):35-43.

PMID:
7518356
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk